戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 esponse effects, using undiluted and diluted smallpox vaccine.
2 es suggest the feasibility of a multiprotein smallpox vaccine.
3 uraging result for this candidate attenuated smallpox vaccine.
4 ssfully revaccinated with diluted (<or=1:10) smallpox vaccine.
5  if they or their close contacts receive the smallpox vaccine.
6 cords and defined as receiving 1 dose of the smallpox vaccine.
7 n of a safe alternative to the existing live smallpox vaccine.
8 f 1056 healthy adults after a single dose of smallpox vaccine.
9 he polyclonal human antibody response to the smallpox vaccine.
10                        Vaccinia virus is the smallpox vaccine.
11 ination and thus provide a safer alternative smallpox vaccine.
12  that this is a fundamental attribute of the smallpox vaccine.
13 ristic of the human antibody response to the smallpox vaccine.
14 wise to exclude the B5 protein from a future smallpox vaccine.
15 er primary immunization with Aventis Pasteur smallpox vaccine.
16  viral neutralization and part of the Dryvax smallpox vaccine.
17 with a 1 : 5 dilution of the Aventis Pasteur smallpox vaccine.
18 infections, and the side effects of existing smallpox vaccines.
19 cal to the success of the next generation of smallpox vaccines.
20 od options for alternative second-generation smallpox vaccines.
21 on assay is required to evaluate alternative smallpox vaccines.
22 lanning the immunologic assessment of future smallpox vaccines.
23 gered rare instances of encephalomyelitis to smallpox vaccines.
24 us complications associated with traditional smallpox vaccines.
25 rant further assessment as candidate subunit smallpox vaccines.
26 ell-mediated immune responses induced by new smallpox vaccines.
27 us includes variola [smallpox] and vaccinia [smallpox vaccine]).
28                                 The licensed smallpox vaccine, ACAM2000, is a cell culture derivative
29 ctive and long-lasting immunity conferred by smallpox vaccines against other orthopoxviruses.
30 is an attenuated virus that is approved as a smallpox vaccine and is in clinical trials as a vector f
31 o examine a possible association between the smallpox vaccine and postvaccination ischemic events, we
32 has led to the production and stockpiling of smallpox vaccine and the immunization of some healthcare
33 vax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccination succ
34 n undiluted or a 1 : 5 or 1 : 10 dilution of smallpox vaccine and who subsequently were tested for pl
35 h for preclinical and clinical trials of new smallpox vaccines and for evaluation of therapeutic agen
36  cross-reactive immune responses elicited by smallpox vaccines and mpox virus infection.
37 provide a benchmark against which new, safer smallpox vaccines and residual immunity can be compared.
38 ings have implications for the design of new smallpox vaccines and the understanding of immune respon
39 rus Ankara (MVA) is a replication-restricted smallpox vaccine, and numerous clinical studies of recom
40 ing made in smallpox laboratory diagnostics, smallpox vaccines, and antiviral medications.
41 conclude that the protection afforded by the smallpox vaccine anti-EV response is predominantly media
42 ry vaccine trials of diluted Aventis Pasteur smallpox vaccine (APSV) demonstrated that immunization "
43 ual immunity to smallpox and supplies of the smallpox vaccine are being reconstituted.
44 , and IL-6 immune responses after receipt of smallpox vaccine are genetically controlled by HLA genes
45                                              Smallpox vaccine, arguably the most effective vaccine in
46   Practicing physicians should be aware that smallpox vaccine-associated myopericarditis is a real en
47 , public health agencies in the UK have made smallpox vaccines available to individuals at the highes
48       Two independent clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in hea
49 usual entity that has been described for the smallpox vaccine, but only anecdotal case reports have b
50               We studied antibody targets in smallpox vaccine by developing potent neutralizing antib
51     Preclinical studies to date with subunit smallpox vaccine candidates, however, have been limited
52                                  None of the smallpox vaccines caused illness in this model, and all
53  and immunogenicity of the new cell-cultured smallpox vaccine (CCSV) to that of the calf-lymph derive
54                                              Smallpox vaccines containing vaccinia virus elicit stron
55 erum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infecti
56                                          The smallpox vaccine Dryvax, a live vaccinia virus (VACV), p
57                                          The smallpox vaccine Dryvax, which consists of replication-c
58 ration as an alternative to the conventional smallpox vaccine Dryvax.
59 r had recently received a booster of current smallpox vaccine (Dryvax) but not in VV-naive donors.
60 stic alternatives to the currently available smallpox vaccine (Dryvax).
61  of the human humoral immune response to the smallpox vaccine (Dryvax).
62 als (n = 1071) who received a single dose of smallpox vaccine (Dryvax, Wyeth Laboratories) and examin
63                                    While the smallpox vaccine, Dryvax or Dryvax-derived ACAM2000, hol
64                 Vaccination with the current smallpox vaccine, Dryvax, produces protective immunity b
65          There is renewed interest in use of smallpox vaccine due to the potential for a bioterrorist
66                                         Mpox/smallpox vaccine effectiveness was high, inclusive of th
67   Both first-generation and third-generation smallpox vaccines elicited vaccinia virus-reactive and m
68 ding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans
69                   Vaccinia virus (VACV), the smallpox vaccine, encodes many proteins that subvert the
70 dual MHC-II-restricted vaccinia virus (VACV, smallpox vaccine) epitopes revealed that CD4(+) T cell h
71      MVA is a promising candidate as a safer smallpox vaccine, even for immunocompromised individuals
72 omparable maximum titer reached in naive and smallpox vaccine-experienced vaccinees.
73  virus ankara (MVA), a candidate replacement smallpox vaccine, failed to induce responses to two of t
74  heightened the need to develop an effective smallpox vaccine for immunization of the general public.
75 several nations are developing stockpiles of smallpox vaccine for use in the event the disease is rei
76 study, we tested current and investigational smallpox vaccines for safety, induction of anti-OPXV ant
77 nced and partially assembled five genomes of smallpox vaccines from the nineteenth century.
78 e evolutionary relationship of the different smallpox vaccine genomes during the centuries.
79                 The results demonstrate that smallpox vaccine given by bifurcated needle induces stro
80 his study measured the ability of a standard smallpox vaccine, given by scarification (by bifurcated
81 n of Wyeth Dryvax vaccine and Sanofi Pasteur smallpox vaccine, given that the resulting morbidity sho
82 tion of smallpox, vaccination rates with the smallpox vaccine have significantly dropped.
83 omised individuals, a group for whom current smallpox vaccines have an unacceptable safety profile.
84  cells underwent 3-week-long expansion after smallpox vaccine immunization and displayed simple reexp
85 munospot assay [ELISPOT]) immune response to smallpox vaccine in 1076 immunized individuals.
86 ortion of individuals who should not receive smallpox vaccine in a preexposure vaccination campaign.
87 es regulating the humoral immune response to smallpox vaccine in both Caucasians and African American
88 horsepox and horsepox-related viruses as the smallpox vaccine in the nineteenth century.
89           This evaluation of different human smallpox vaccines in cynomolgus macaques helps to provid
90 model for the safety and efficacy testing of smallpox vaccines in pre- and postexposure vaccine testi
91  considering smallpox vaccination and better smallpox vaccines in the future.
92 e or cytokine receptor gene polymorphisms in smallpox vaccine-induced adaptive immunity.
93 IL18R1 and IL18 genetic loci for broad-based smallpox vaccine-induced adaptive immunity.
94   Our results demonstrate that variations in smallpox vaccine-induced cytokine responses are modulate
95 similarities of antigenic protein targets of smallpox vaccine-induced responses in humans and prairie
96                    The mechanisms underlying smallpox vaccine-induced variations in immune responses
97 cinia virus (VACV), the virus comprising the smallpox vaccine, induces memory CD8(+) T cells that pro
98                         APSV is an effective smallpox vaccine inducing strong humoral and cellular im
99 tis and pericarditis: clozapine, mesalazine, smallpox vaccine, influenza vaccine, and COVID-19 mRNA v
100 minated by vaccination; however, because the smallpox vaccine is a live orthopoxvirus vaccine (vaccin
101                           The currently used smallpox vaccine is associated with a high incidence of
102                                          The smallpox vaccine is associated with more serious adverse
103                                              Smallpox vaccine is considered a gold standard of vaccin
104                                              Smallpox vaccine is contraindicated in immunosuppression
105  Studying the immune protection mechanism of smallpox vaccine is important for understanding the basi
106                        New information about smallpox vaccine is included in this year's review becau
107 le, and the development of a safer effective smallpox vaccine is necessary.
108                  Moreover, the safety of the smallpox vaccine is of great concern, as complications m
109                                          The smallpox vaccine is the prototypic vaccine, yet the vira
110                     One approach for a safer smallpox vaccine is to utilize recombinant subunits rath
111                                          The smallpox vaccine is widely considered the gold standard
112             Vaccinia virus, the basis of the smallpox vaccine, is one of the largest viruses to repli
113 onses upon vaccination, since its use as the smallpox vaccine led to the eradication of one of the wo
114 in IOC (VACV-IOC) was the seed strain of the smallpox vaccine manufactured by the major vaccine produ
115 enuated cell culture-adapted Lister vaccinia smallpox vaccine missing the B5R protein and licensed fo
116                         The third generation smallpox vaccine modified vaccinia Ankara, manufactured
117 MVA-BN increased MPXV neutralizing titers in smallpox vaccine-naive vaccinees, with a comparable maxi
118 etween HLA alleles and 15 immune outcomes to smallpox vaccine on a per-locus and a per-allele level.
119             Why this is the case and how the smallpox vaccine overcomes this challenge remain incompl
120                                              Smallpox vaccines provide immunity against monkeypox.
121   These properties, shared with the existing smallpox vaccine, provide a basis for further evaluation
122                                              Smallpox vaccine provided protection against both infect
123                            Thus, the current smallpox vaccine provides long-lasting CD4 help that may
124 ntially lethal complication that develops in smallpox vaccine recipients with severely impaired cellu
125 across four groups: Dryvax (first-generation smallpox vaccine) recipients vaccinated 40-80 years ago,
126 d 40-80 years ago, JYNNEOS (third-generation smallpox vaccine) recipients vaccinated within the past
127 es in mediating adaptive immune responses to smallpox vaccine remains unknown.
128 ation in 1980, developing safe and effective smallpox vaccines remains an active area of research due
129               Vaccinia virus (VV), the virus smallpox vaccine, replicates in the cytoplasm of infecte
130 t 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been perf
131           In this study, we demonstrate that smallpox vaccine-specific memory B cells last for >50 ye
132  To evaluate the humoral immune responses to smallpox-vaccine stocks currently available in the Unite
133  recent common ancestor, probably an ancient smallpox vaccine strain related to horsepox virus.
134 rization of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox era
135 ne (Wyeth/IL-15/PA) using the licensed Wyeth smallpox vaccine strain that is efficacious against both
136          Altogether, these data indicate the smallpox vaccine succeeds in generating strong neutraliz
137          Therefore, the development of safer smallpox vaccines that can match the immunogenicity and
138     Therefore, the search for new-generation smallpox vaccines that combine low pathogenicity, immune
139 outbreak triggered vaccination efforts using smallpox vaccines that were approved for mpox, including
140  virus strains, including the current clonal smallpox vaccine, that the ability of a strain to spread
141 inning with Edward Jenner's discovery of the smallpox vaccine, the ever-expanding repertoire of vacci
142 us (VV) as a vector for other Ags and as the smallpox vaccine, there is little information available
143 nisations have identified the need for a new smallpox vaccine to replenish limited stocks of the appr
144 ast five years, and that there is not enough smallpox vaccine to vaccinate everyone in the United Sta
145 esponding to the live yellow fever virus and smallpox vaccines--two highly successful human vaccines.
146                                          The smallpox vaccine using vaccinia virus has been highly su
147 f protective humoral immunity induced by the smallpox vaccine (vaccinia virus [VACV]).
148 f the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent
149 uate the potential to increase the supply of smallpox vaccine (vaccinia virus), we compared the respo
150 rsistent infections, influenza virus and the smallpox vaccine virus (vaccinia virus), were studied.
151                                              Smallpox vaccine was administered by scarification using
152 fied vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis
153 0 years ago as a highly attenuated candidate smallpox vaccine, was recloned from a 1974 passage and e
154 rison of responses to newly produced lots of smallpox vaccine, we evaluated dose-response effects, us
155                          To develop a modern smallpox vaccine, we have adapted vaccinia virus that wa
156 igating the efficacy of various dilutions of smallpox vaccine, we observed the appearance of a papulo
157             Using vaccinia virus (VACV), the smallpox vaccine, we report that the VACV BBK protein A5
158                                     Although smallpox vaccines were rapidly deployed to curb spread a
159  antibody responses that are elicited by the smallpox vaccine, which has enabled the first eradicatio
160                                  Alternative smallpox vaccines with an improved safety profile would

 
Page Top